Xinlitai: JK06 clinical trials conducted overseas demonstrate good safety and efficacy.

Sino Biopharmaceutical announced that its subsidiary SalubrisBio has informed the company that it has presented half of the expansion cohort data for JK06 at the 2026 annual meeting of the American Association for Cancer Research (AACR). The data shows that JK06 has demonstrated good safety and efficacy in unresectable locally advanced or metastatic tumor patients, including non-small cell lung cancer and breast cancer. Among the 38 evaluable non-small cell lung cancer patients, the objective response rate was 26%, and among the 19 evaluable breast cancer patients, the ORR was 26%. In terms of safety, overall tolerability was good, with no Grade 4 or 5 adverse events observed. Currently, JK06 is advancing dose expansion phase studies in Europe.